- Home
- PMM vs BWAY Comparison
PMM vs BWAY Comparison
Compare PMM & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- BWAY
- Stock Information
- Founded
- PMM 1989
- BWAY 2003
- Country
- PMM United States
- BWAY Israel
- Employees
- PMM N/A
- BWAY N/A
- Industry
- PMM Investment Managers
- BWAY Medical/Dental Instruments
- Sector
- PMM Finance
- BWAY Health Care
- Exchange
- PMM Nasdaq
- BWAY Nasdaq
- Market Cap
- PMM 251.7M
- BWAY 280.7M
- IPO Year
- PMM N/A
- BWAY 2019
- Fundamental
- Price
- PMM $6.17
- BWAY $16.89
- Analyst Decision
- PMM
- BWAY Strong Buy
- Analyst Count
- PMM 0
- BWAY 2
- Target Price
- PMM N/A
- BWAY $18.00
- AVG Volume (30 Days)
- PMM 118.3K
- BWAY 76.3K
- Earning Date
- PMM 01-01-0001
- BWAY 11-11-2025
- Dividend Yield
- PMM 4.68%
- BWAY N/A
- EPS Growth
- PMM N/A
- BWAY 515.14
- EPS
- PMM 0.23
- BWAY 0.11
- Revenue
- PMM N/A
- BWAY $46,084,000.00
- Revenue This Year
- PMM N/A
- BWAY $339.49
- Revenue Next Year
- PMM N/A
- BWAY $21.74
- P/E Ratio
- PMM $26.52
- BWAY $53.75
- Revenue Growth
- PMM N/A
- BWAY 26.50
- 52 Week Low
- PMM $5.00
- BWAY $7.84
- 52 Week High
- PMM $6.42
- BWAY $16.98
- Technical
- Relative Strength Index (RSI)
- PMM 52.77
- BWAY 70.40
- Support Level
- PMM N/A
- BWAY $15.01
- Resistance Level
- PMM $6.10
- BWAY $16.09
- Average True Range (ATR)
- PMM 0.05
- BWAY 0.68
- MACD
- PMM -0.19
- BWAY -0.06
- Stochastic Oscillator
- PMM 99.84
- BWAY 95.82
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.